| Article Access Statistics | | | Viewed | 3802 | | | Printed | 130 | | | Emailed | 0 | | | PDF Downloaded | 174 | | | Comments | [Add] | | | Cited by others | 5 | | |
|
Click on image for details.
|
|
| RESEARCH ARTICLE |
|
| Year : 2021 | Volume
: 53
| Issue : 1 | Page : 6-12 |
Denosumab biosimilar in postmenopausal osteoporotic women: A randomized, assessor-blind, active-controlled clinical trial
Inderjeet Singh1, Vinu Jose1, Ronak Patel2, Sumit Arora3
1 Clinical Development and Medical Affairs, Intas Pharmaceuticals Ltd. (Biopharma)., Ahmedabad, Gujarat, India
2 Biostatistics and Programming, Lambda Therapeutic Research Ltd., Ahmedabad, Gujarat, India
3 Clinical Trial Operations and Medical Services, Lambda Therapeutic Research Ltd., Ahmedabad, Gujarat, India
Correspondence Address:
Dr. Vinu Jose
Clinical Development and Medical Affairs, Intas Pharmaceuticals Ltd. (Biopharma), Moraiya, Ahmedabad, Gujarat
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijp.IJP_346_19
OBJECTIVE: The study assessed the efficacy, safety, pharmacokinetic (PK), and immunogenicity profiles of denosumab-biosimilar and denosumab-reference in postmenopausal osteoporotic women from India.
MATERIALS AND METHODS: In this randomized, assessor-blind, active-control, multicenter trial, 114 patients were randomly allocated to receive denosumab-biosimilar (n = 58) or denosumab-reference (n = 56) at a subcutaneous dose of 60 mg every 6 months, for a year. Vitamin D and oral calcium were given daily. Lumbar spine bone mineral density (BMD) change was the primary end point.
RESULTS: Of 114 randomized patients, 111 (denosumab-biosimilar, n = 56; denosumab-reference, n = 55) completed the study. All 114 patients were part of safety and immunogenicity analyses, 110 (denosumab-biosimilar, n = 56; denosumab-reference, n = 54) were part of efficacy analysis, and 20 (denosumab-biosimilar, n = 10; denosumab-reference, n = 10) were part of PK analysis. The bone mineral density (BMD) (lumbar spine) percent change at 1 year with denosumab-biosimilar and denosumab-reference (7.22 vs. 7.62; difference:−0.40; 95% confidence interval: −5.92, 5.12) showed no statistically relevant difference. Likewise, alkaline phosphatase (bone-specific) and PK parameters also did not show statistically relevant differences. Adverse events were reported in 44.83% of patients on denosumab-biosimilar versus 33.93% of patients on denosumab-reference; most events were mild or moderate and not related to the study drugs. No patients showed anti-denosumab antibody positivity.
CONCLUSIONS: Denosumab-biosimilar and denosumab-reference showed biosimilarity in osteoporotic postmenopausal women. Availability of denosumab-biosimilar provides a treatment alternative for patients.
[FULL TEXT] [PDF]*
|
